RxDoctor Payments Data

Michael Sheinin, DO

Internal Medicine · Las Vegas, NVNPI 1023467214

Payments from drug & device makers

$594in general payments, 2019–2025

Across 8 payments — averaging $74.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$230
  • Silk Road Medical, Inc.$145
  • Incyte Corporation$125
  • Paratek Pharmaceuticals, Inc.$64
  • Johnson & Johnson$17
  • Pfizer$13

What the payments were for

  • Food & beverage$594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$594 in reported general payments places this provider in the 65th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$683,842
Medicare patients
837
Services billed
6,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$42,904
EntrestoSacubitril/Valsartan25$20,711
BrilintaTicagrelor15$11,475
JardianceEmpagliflozin19$9,436
TrulicityDulaglutide13$9,072
JanuviaSitagliptin Phosphate14$6,701
JanumetSitagliptin Phos/Metformin Hcl12$3,380
Sevelamer Carbonate13$2,555
Humalog Kwikpen U-100Insulin Lispro12$1,540
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,333
Atorvastatin Calcium155$1,137
Ultra-Fine Nano Pen NeedlePen Needle, Diabetic15$1,030
Pantoprazole Sodium87$767
Albuterol Sulfate HfaAlbuterol Sulfate25$746
Omeprazole40$621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$42,90457 claims
Boehringer IngelheimJardiance$230$9,43619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →